Epigenomics AG
EPGNF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Revenue | $67 | $68 | $70 | $134 |
| % Growth | -1.5% | -2.7% | -47.8% | – |
| Cost of Goods Sold | $7 | $7 | $5 | $38 |
| Gross Profit | $60 | $61 | $65 | $96 |
| % Margin | 89.6% | 89.8% | 92.9% | 71.6% |
| R&D Expenses | $723 | $723 | $324 | $1,121 |
| G&A Expenses | $0 | $0 | $0 | $4,767 |
| SG&A Expenses | $1,355 | $1,355 | $705 | $4,767 |
| Sales & Mktg Exp. | $0 | $0 | $705 | $0 |
| Other Operating Expenses | -$7,863 | $0 | $0 | $0 |
| Operating Expenses | -$5,785 | $1,841 | $2,837 | $5,888 |
| Operating Income | $1,963 | $2,164 | -$2,634 | -$5,669 |
| % Margin | 2,924.5% | 3,176.6% | -3,762.9% | -4,230.6% |
| Other Income/Exp. Net | -$83 | -$284 | $2 | $78 |
| Pre-Tax Income | $1,880 | $1,880 | -$2,632 | -$5,591 |
| Tax Expense | -$1 | -$1 | $1 | $0 |
| Net Income | $1,880 | $1,880 | -$2,633 | -$5,591 |
| % Margin | 2,801.6% | 2,760.4% | -3,761.4% | -4,172.4% |
| EPS | 2.2 | 2.2 | -3.09 | -6.55 |
| % Growth | 0% | 171.2% | 52.8% | – |
| EPS Diluted | 2.2 | 2.2 | -3.09 | -6.55 |
| Weighted Avg Shares Out | 853 | 853 | 853 | 853 |
| Weighted Avg Shares Out Dil | 853 | 853 | 853 | 853 |
| Supplemental Information | – | – | – | – |
| Interest Income | $22 | $22 | $9 | $85 |
| Interest Expense | $0 | $0 | $7 | $7 |
| Depreciation & Amortization | -$639 | -$639 | $579 | $1,262 |
| EBITDA | $190 | $2,564 | -$2,046 | -$4,322 |
| % Margin | 283.2% | 3,764.9% | -2,922.9% | -3,225.4% |